Health News4 years ago
ESMO: New Trodelvy breast, bladder cancer data show why Gilead’s going big for Immunomedics
Compared with the spate of multibillion-dollar buyouts last year, biopharma M&A has been relatively quiet in 2020—until last week, when Gilead Sciences surprised the market with its...